|Basic InformationMore InformationLatest News|College Women More Prone to Problem Drinking Than Men: StudyIs Menopause Overlooked in U.S. Medical Schools?Young Women Less Healthy Than Men Before Heart Attack: StudyCombo Drug Therapy May Work Best to Strengthen Bones: StudyHealth Tip: Manage Menopause'Eating More Protein' Strategy Helps Women Lose WeightJust How Might Exercise Lower Breast Cancer Risk?Can High-Protein, Low-Carb Diet Boost Fertility Treatment?Potentially Toxic Metals Present in Lip CosmeticsLow-Dose 'Pill' Linked to Pain During Orgasm, Study FindsExercise May Lower Older Women's Risk for Kidney StonesNearly One-Third Don't Pick Up New Osteoporosis RxWhite House to Challenge Ruling on Unlimited Access to 'Morning-After' PillLipsticks, Glosses Contain Toxic Metals: ReportFDA Approves 'Morning-After' Pill Without a PrescriptionImplants May Delay Breast Cancer Detection, Raise Death RiskKeep Beauty Regimen Safe During Pregnancy, Doctor AdvisesPediatrician Group Issues Home Birth Policy StatementEven Light Smoking Increases Risk of RA Among WomenMammo Rates Unchanged Despite Controversial GuidelinesFamily Doc Counseling Fails to Lift QoL for Abused WomenEndometriosis Surgery Linked to Lower Ovarian Cancer RiskLaparoscopic Hysterectomy Rates on Rise Over Past DecadeMenopause-Like Woes Hinder Breast Cancer Treatment: StudyAACR: Exercise Tied to Reduced Estrogens Post-MenopauseNew Clues to How Exercise May Reduce Breast Cancer RiskDoctors Too Pap-Happy, Survey SuggestsFor Older Women, Missed Mammograms Tied to Worse Breast Cancer OutcomesExperimental Vaccine Shows Promise for Ovarian CancerFederal Judge Rules FDA Must Lift Restrictions on Plan BJudge: Make Morning-After Pill Available to All FemalesStudy Pinpoints Women at Risk for Blood Clots From PregnancyBreast Cancer Gene Tests Won't Help Most Women: ReportPhysical Activity Improves Sleep for Menopausal WomenMore Evidence Shows Hormone Therapy May Increase Breast Cancer RiskArtificial Ovaries Could Potentially Deliver Hormone TherapyNew Method May Help Pinpoint Woman's Final Menstrual PeriodHormone Pills in Menopause May Carry Gallstone Side EffectsFalse-Positive Mammograms Can Trigger Long-Term DistressData Insufficient to Link Declines in Breast Cancer, HRT UseMammograms Every Other Year OK for Women Over 50: StudyAbout 14 Percent of Moms Face Postpartum DepressionHigh-Fat Dairy Linked to All-Cause, Breast Cancer MortalityRobotic Surgery for Hysterectomy Often Not Best Option, Ob/Gyn Group SaysNight Shift Linked to Raised Risk of Ovarian CancerDNA Test Shows Promise in Guiding Advanced Breast Cancer CareObese New Mothers May Have Higher Heart Attack, Stroke RiskNew Pap Guidelines May Miss Aggressive Cancer in Young Women: StudyNonheme Iron Intake Linked to Reduced Risk of PMSMotherhood May Spur Obsessive-Compulsive Behavior in SomeQuestions and AnswersLinksBook Reviews
FDA Gives Nod to New Breast Cancer Drug
Updated: Jul 20th 2012
FRIDAY, July 20 (HealthDay News) -- The U.S. Food and Drug Administration on Friday approved the use of the drug Afinitor (everolimus) for use by women with a particular form of advanced breast cancer.
It's the first time that a drug from this class of medications, called mTOR inhibitors, has been approved for this disease, the FDA said. Afinitor is already used to fight advanced kidney and neuroendocrine tumors, as well as a handful of rarer cancers.
The medicine is only approved for use by postmenopausal women battling an advanced form of estrogen-sensitive tumor known as hormone-receptor positive, HER2-negative breast cancer. Even then, Afinitor should only be used after such patients have already experienced a recurrence or progression of the tumor following prior treatment with Femara (letrozole) or Arimidex (anastrozole), the FDA said.
Adding Afinitor -- which has proven effective for other cancers -- to therapy might help these patients, the agency said.
"Afinitor is another example of the value of continuing to study drugs in additional types of cancer after their initial approval," Dr. Richard Pazdur, director of the Office of Hematology and Oncology Products in the FDA's Center for Drug Evaluation and Research, said in an agency news release.
According to the FDA, approval was based on a clinical trial involving 724 postmenopausal women with advanced breast cancer that had spread despite prior treatment with Femara or Arimidex. All of the women also took the standard breast cancer drug Aromasin (exemestane) during the trial.
The trial found that adding in Afinitor boosted average progression-free survival (the time the women lived without any progression of their tumor) by 4.6 months compared to women taking an inactive placebo.
There was a downside to using Afinitor, however: According to the FDA, side effects included rash, fatigue, diarrhea, loss of appetite and mouth ulcers. These effects were more common in women aged 65 or older, so the agency says older patients should be monitored more closely if they take Afinitor.
Dr. Stephanie Bernik, chief of surgical oncology at Lenox Hill Hospital in New York City, commented on Afinitor's approval.
"It is exciting that there continues to be advances in treating breast cancer that are allowing patients to survive longer, even in the face of metastatic disease," Bernik said. "The improved treatment for advanced-stage breast cancer offers women hope that a treatment to completely stabilize, or even eradicate the disease, might be achievable within their lifetime."
The drug is marketed by Novartis Pharmaceuticals Corp., based in East Hanover, N.J.
Find out more about breast cancer at the U.S. National Cancer Institute.
This article: Copyright © 2012 HealthDay. All rights reserved.